To analyze the clinical value of Jinlida combined with insulin therapy on type 2 diabetes. Methods:Totally 94 cases of patients with type 2 diabetes in the hospital from October 2012 to May 2015 were divided into 2 groups randomly, observation group and control group, each 47 cases. The observation group was given insulin aspart 50 injection, and the control group Jinlida. After treatment, two groups of patients′ blood glucose and total efficacy were compared. Results:After intervention, 2 hPG, FPG, HbA1c, HOMA IR, and HOMA-beta of the 2 groups were significantly different from those before treatment (P<0.01); The observation group′s 2 hPG， FPG, HbA1c, HOMA IR, and HOMA-beta were very largely different than those of the control group with statistical significance (P<0.01); The observation group′s total effecacy was significantly better than that of the control group (P<0.05). Conclusion:The combination of Jinlida and insulin aspart 50 significantly reduced the blood sugar in type 2 diabetes patients and improved the patient′s corresponding islet function with outstanding clinical value.